Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth

Archives of Gynecology and Obstetrics

Volumn 291, Issue 1, 2015, Pages 143-150

  Song, Yue ^a   Xin, Xing ^a   Zhai, Xingyue ^a   Xia, Zhijun ^a   Shen, Keng ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Flavopiridol; Human ovarian carcinoma; Taxol; Therapy

Indexed keywords

CYCLIN D1; FLAVOPIRIDOL; PACLITAXEL; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CAPILLARY DENSITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; ANIMAL; DRUG EFFECTS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUNEL ASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FLAVONOIDS; HUMANS; IN SITU NICK-END LABELING; MICE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PIPERIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930241305     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-014-3408-0     Document Type: Article

References (17)

1. Armstrong DK (2013) New issues in systemic therapy for ovarian cancer. J Natl Compr Canc Netw 11:690–693
2. Jain SK, Bharate SB, Vishwakarma RA (2012) Cyclin-dependent kinase inhibition by flavoalkaloids. Mini Rev Med Chem 12:632–649
3. Nelson DM, Joseph B, Hillion J, Segal J, Karp JE, Resar LM (2011) Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 52:1999–2006
4. Keskin H, Garriga J, Georlette D, Graña X (2012) Complex effects of flavopiridol on the expression of primary response genes. Cell Div 7:11
5. Senderowicz AM (2005) Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 63:183–206
6. Schwartz GK (2005) Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23:4499–4508
7. Baumann KH, Kim H, Rinke J, Plaum T, Wagner U, Reinartz S (2013) Effects of alvocidib and carboplatin on ovarian cancer cells in vitro. Exp Oncol 35:168–173
8. Nagaria TS, Williams JL, Leduc C, Plaum T, Wagner U, Reinartz S (2013) Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. Neoplasia 15:939–951
9. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9–19
10. Stephens DM, Ruppert AS, Maddocks K et al (2013) Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res 37:1195–1199
11. Gallorini M, Cataldi A, di Giacomo V (2012) Cyclin-dependent kinase modulators and cancer therapy. BioDrugs 26:377–391
12. Pepper C, Thomas A, Hog T, Fegan C, Bentley P (2001) Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukemia. Br J Haematol 114:70–77
13. Bible KC, Bible RH, Kottke TJ et al (2000) Flavopiridol binds to duplex DNA. Cancer Res 60:2419–2428
14. Bible KC, Kaufmann SH (1996) Flavopiridol, a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856–4861
15. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentration of paclitaxel(Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816–825
16. Bible KC, Kaufmann SH (1997) Cytotoxic synerge between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57:3375–3380
17. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK (2003) Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2:549–555